Terazosin polymorph and pharmaceutical composition
AssigneeAbbott Laboratories
InventorsGlenn A. Meyer, John F. Bauer
Life of this patent
Estimating the term…
Abstract
A novel anhydrous crystalline polymorph of 1-(4-amino-6,7-dimethoxy- 2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride is disclosed, together with pharmaceutical formulations containing the compound. The novel polymorph exhibits a diminished food effect when administered to human subjects.
Claims8
A crystalline polymorph of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine monohydrochloride characterized by peaks in the powder X-ray diffraction pattern at values of 2 theta of 5.5.degree..+-.0.2.degree., 10.6.degree..+-.0.2.degree., 11.1.degree..+-.0.2.degree., 16.7.degree..+-.0.2.degree., 19.4.degree..+-.0.2.degree., 21.3.degree..+-.0.2.degree., 22.0.degree..+-.0.2.degree., 22.7.degree..+-.0.2.degree., 23.1.degree..+-.0.2.degree., 24.4.degree..+-.0.2.degree., 24.9.degree..+-.0.2.degree., 25.5.degree..+-.0.2.degree., and 27.8.degree..+-.0.2.degree..
Dependencies are inferred from the claim text.